Molecular weight
296.4 Da
FDA-approved for breast cancer. Steroidal structure provides mild androgenic effects alongside estrogen suppression. Preferred by some clinicians for TRT management due to gentler estrogen floor.
Steroidal irreversible aromatase inactivator (Type I). Binds permanently to aromatase active site — enzyme is permanently inactivated, recovery requires new enzyme synthesis (~72h). Androgenic properties (weak) differentiate from non-steroidal AIs. Does not suppress estrogen below physiologic floor as aggressively as anastrozole.
Irreversible aromatase inactivation; steroidal; mild androgenic effects; 72h enzyme recovery; FDA-approved breast cancer.
Research data is not a treatment plan. If you are considering Exemestane, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.
Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.Interactive tools for this compound:
Reconstitution calculator · Full deep dive · Peptide fundamentals